Detalhe da pesquisa
1.
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
N Engl J Med
; 387(4): 310-320, 2022 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35830649
2.
Revisiting the predictive role of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography on treatment outcome in early-stage favorable Hodgkin lymphoma.
Hematol Oncol
; 41(4): 608-611, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37805963
3.
Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial.
Hematol Oncol
; 41(3): 415-423, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36534947
4.
Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.
Int J Mol Sci
; 24(17)2023 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37685994
5.
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Blood
; 135(10): 735-742, 2020 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31945149
6.
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Haematologica
; 107(5): 1086-1094, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162178
7.
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
N Engl J Med
; 378(4): 331-344, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29224502
8.
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.
Hematol Oncol
; 39(2): 185-195, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462822
9.
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Ann Hematol
; 100(10): 2547-2556, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34327561
10.
Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose/positron-emission tomography in advanced Hodgkin lymphoma.
Q J Nucl Med Mol Imaging
; 65(4): 410-415, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28750493
11.
Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.
Hematol Oncol
; 38(4): 501-508, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32602970
12.
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Eur J Nucl Med Mol Imaging
; 45(5): 712-719, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29270787
13.
ΔSUVmax for interim PET in DLBCL: old is new.
Blood
; 135(25): 2202-2203, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32556130
14.
Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report.
Hematol Oncol
; 35(4): 875-877, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27539158
15.
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Eur J Nucl Med Mol Imaging
; 43(3): 414-21, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26475305
16.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Blood
; 122(23): 3759-66, 2013 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24085766
17.
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
Haematologica
; 100(6): 786-93, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25749825
18.
FDG PET/CT imaging as a biomarker in lymphoma.
Eur J Nucl Med Mol Imaging
; 42(4): 623-33, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25573631
19.
The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).
Am J Hematol
; 90(6): 499-503, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25720750
20.
Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.
Biol Blood Marrow Transplant
; 20(5): 717-23, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24525280